Drugs / interleukin-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001270 | Jun 1991 → Mar 2000 | breast neoplasm, lymphoma, metastatic neoplasm, neoplasm of testis | National Cancer Institute (NCI) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2025-04-25 | Cantargia AB | Results Cantargia presenterar lovande prekliniska resultat på anti-IL1RAP ADC vid en stor cancerkonferens cantargia.com ↗
Prekliniska data för den nya anti-IL1RAP ADC:n visar effektiv hämning av tumörtillväxt med potent dosberoende antitumöraktivitet i en tumörmodell som uttrycker högt IL1RAP. |
| 2020-07-14 | XBiotech, Inc. | Results XBiotech Announces Discovery that Blocking Interleukin-1a Reduces Brain Injury and Neurological Deficit After Stroke xbiotech.com ↗
This study demonstrates the importance of IL-1α in mediating the damages caused by ischemic stroke and the efficacy of IL-1α blockade in improving outcome after transient cerebral ischemia in mice. |
| 2019-10-23 | Rigel Pharmaceuticals | Results Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call rigel.com ↗
In addition to positive tolerability and pharmacokinetic data, R835 showed consistent inhibition of cytokine production in an LPS (lipopolysaccharide) challenge which was designed to gauge the molecule's impact on inflammatory stimulation. |
| 2018-12-13 | XBiotech, Inc. | Results XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study xbiotech.com ↗
The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. |
| 2018-08-27 | XBiotech, Inc. | Results XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart Attacks xbiotech.com ↗
XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings that point toward a white blood cell-derived interleukin-1 alpha (IL-1⍺) as a cause of blood clots that could lead to heart attacks or strokes. |
| 2017-05-30 | XBiotech, Inc. | Results Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer xbiotech.com ↗
These results provide new insight on the active role for interleukin-1 regulation in disease progression in colorectal cancer and could help us create more personalized approaches to treatment of the disease. |
| 2016-05-24 | XBiotech, Inc. | Results XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology's World Congress on Gastrointestinal Cancer xbiotech.com ↗
today said its upcoming presentation of pivotal Phase III data for Xilonix(TM), the Company's lead therapy developed for the treatment of advanced colorectal cancer, will include positive preliminary findings on survival. |
| 2015-11-03 | AbbVie | Results AbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with More Than 40 Abstracts on HUMIRA® (adalimumab) and Investigational Medicines Across Multiple Inflammatory Diseases abbvie.com ↗
Dual Variable Domain-Immunoglobulin (Dvd-Ig™) Abt-981 Simultaneously And Dose-Dependently Inhibits Interleukin-1 Αlpha And -1 Βeta In Subjects With Knee Osteoarthritis |
| 2015-04-01 | XBiotech, Inc. | Results XBiotech Announces Publication of Positive Clinical Results for Xilonix™ in Non-Small Cell Lung Cancer xbiotech.com ↗
Radiographic evidence of anti-tumor effect was observed, in addition to improvements in lean body mass and quality of life. |
| 2015-03-04 | XBiotech, Inc. | Results XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology xbiotech.com ↗
XBiotech announced today that results from its Phase II pilot study in patients with moderate to severe plaque psoriasis have been published in JAMA Dermatology. |
| 2013-11-27 | VetStem Biopharma, Inc. | Results Dr. Ross Rich of Cave Creek Equine Recently Presented the Outcome of 42 Horses with Stifle Injuries Treated with Vet-Stem Regenerative Cell Therapy vetstem.com ↗
Dr. Rich’s findings demonstrated good to excellent (over 64% of the subjects) long-term return to full work, in horses with lameness caused by stifle injuries, treated with arthroscopy, stem cell therapy by Vet-Stem, and IRAP. |
| 2010-11-10 | XOMA (US) LLC | Results Positive XOMA 052 Results in Inflammatory Eye Disease - Behcet's Uveitis - Presented at American College of Rheumatology Scientific Meeting xoma.com ↗
Further, cytokine data showed, as compared to baseline, reduced levels of IL-1 beta, IL-1 alpha and IL-6 and increased levels of interferon gamma. |
| 2010-06-22 | XOMA (US) LLC | Results Journal Article in Endocrinology Highlights Preclinical XOMA 052 Data in Type 2 Diabetes xoma.com ↗
With results demonstrating reduction in total cholesterol without decreasing high density lipoprotein, also referred to as 'good cholesterol', the data also highlight the potential application of IL-1 beta inhibition in the treatment of cardiovascular diseases. |
| 2010-04-30 | XOMA (US) LLC | Results XOMA 052 Mechanism of Action Results Published in Journal of Biological Chemistry xoma.com ↗ |
| 2009-06-08 | XOMA (US) LLC | Results XOMA Presents Data At ADA Demonstrating Improvement in Diabetes and Inflammatory Measures in Animal Model With XOMA 052 xoma.com ↗
The data reported today clearly show the potential for XOMA 052 to improve glucose control, beta cell function and survival, and insulin resistance without contributing to weight gain. |
| 2009-05-26 | XOMA (US) LLC | Results XOMA Announces Clinical and Preclinical Presentations At American Diabetes Association 69th Scientific Sessions xoma.com ↗
Free fatty acids induce a pro-inflammatory response in islets via the abundantly expressed interleukin-1 receptor I. |
All press releases naming this drug 18 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001270 ↗ |